[ALS Association](https://www.als.org)

November 2026 (Letter of Intent) | February 2027 (Full proposal, by invitation only)

Up to $1,000,000 total over 2–3 years per award; indirect costs capped at 10% of direct costs.

Supports early-stage clinical trials and imaging tracer studies to accelerate development of new ALS therapies.

This is a forecasted opportunity; all dates are projected and subject to change.

--- ## Description The Hoffman ALS Clinical Trial Awards Program, funded by the ALS Association, is designed to accelerate the development of new and improved therapies for amyotrophic lateral sclerosis (ALS). The program provides substantial support for early- to mid-stage (phase 1 or phase 2a) biomarker-driven clinical trials of novel or repurposed therapeutics, as well as early trials of imaging tracers. The goal is to generate critical data on safety, dosing, and biomarkers, thereby "de-risking" subsequent drug development stages and making projects more attractive for follow-on investment and larger trials. Both disease-modifying and symptomatic approaches are eligible, with a strong emphasis on robust biomarker strategies and a clear plan for clinical development. --- ## Due Dates - **Letter of Intent (anticipated):** November 2026 - **Full Proposal (by invitation only, anticipated):** February 2027 *All dates are projected based on the annual cycle; check the program page for updates.* --- ## Funding Amount - **Maximum award:** Up to $1,000,000 total (inclusive of direct and indirect costs) - **Project duration:** 2 or 3 years - **Indirect costs:** Capped at 10% of total direct costs - **Payment structure:** For 2-year projects, $500,000 per year; for 3-year projects, $500,000 in year 1, $250,000 in years 2 and 3 - **Co-funding:** Applicants are encouraged to seek additional funding sources to fully cover trial costs --- ## Eligibility - **Eligible applicants:** Academic and industry investigators with the necessary skills, knowledge, and resources; postdoctoral fellows are not eligible as PIs - **Eligible organizations:** U.S. and non-U.S. public and private non-profit entities (universities, hospitals, research institutes, government agencies) and for-profit companies (biotech/pharma) - **Project requirements:** Must be early- to mid-phase interventional trials (phase 1 or 2a) focusing on ALS therapeutics or imaging tracers; must include a robust biomarker strategy and integrated development plan - **Ineligible projects:** Non-pharmacological, surgical, observational, natural history, or expanded access protocol studies --- ## Application Process - **Phase 1:** Submit a Letter of Intent (LOI), approximately 3–4 pages, outlining the target biology, therapeutic/tracer, trial design, biomarker strategy, and development/commercialization plan - **Phase 2:** Selected applicants will be invited to submit a full proposal (up to 14 pages), including detailed scientific and business plans, budget, and required attachments (biosketches, letters of collaboration, regulatory documents) - **Submission platform:** All materials must be submitted through [ProposalCentral](https://proposalcentral.com/) - **Review process:** LOIs are reviewed for fit and impact; invited full proposals are peer-reviewed by external experts and require final approval by the ALS Association Research Committee --- ## Additional Information - **Regulatory requirements:** IND (or equivalent) approval must be in hand, pending, or planned within 3 months of project start for funded projects - **Reporting:** Semi-annual research progress reports and annual expenditure reports are required - **Intellectual property:** Grantees retain IP rights but the Association expects proportional revenue sharing if the research leads to commercialization (see [Grants Policy Statement](http://www.als.org/Grants-Policy-Statement)) - **Data sharing:** Strongly encouraged, including posting trials on ClinicalTrials.gov and sharing biosamples/data with public repositories --- ## External Links - [Program Page: Hoffman ALS Clinical Trial Awards](https://www.als.org/hugh-and-herbert-hoffman-als-impact-fund/hoffman-als-clinical-trial-awards-program) - [ALS Association Research Funding Opportunities](https://www.als.org/research/researchers/funding-opportunities-researchers) - [Application Portal: ProposalCentral](https://proposalcentral.com/) - [Grants Policy Statement](http://www.als.org/Grants-Policy-Statement) - [Information for Grant Applicants and Awardees](https://www.als.org/research/researchers/information-grant-applicants-and-awardees) --- ## Contact Information | Contact | Details | |------------------------|-----------------------------------------------------| | General Inquiries | [ResearchGrants@als.org](mailto:ResearchGrants@als.org) | | Funder Website | [https://www.als.org](https://www.als.org) | | Phone | +1 800-782-4747 | | Mailing Address | ALS Association, 1300 Wilson Blvd, Suite 600, Arlington, VA 22209, USA | ---

The Hoffman ALS Clinical Trial Awards Program

Sign in to see full grant listing